Robert A. Michael

Chief Executive Officer at AbbVie Inc

Board

Since July 1, 2024

Age

54 years

Tenure

Started his career in Abbott's financial development program in 1993 and was first appointed as an AbbVie corporate officer in March 2017, ultimately advancing through roles such as Vice President, Treasurer, CFO, COO, and President before being named CEO.

Also at AbbVie Inc

Azita Saleki-Gerhardt

Executive Vice President, Chief Operations Officer

DRP

David R. Purdue

Senior Vice President, Controller (effective March 1, 2025)

JRS

Jeffrey R. Stewart

Executive Vice President, Chief Commercial Officer

About

Robert A. Michael has built an extensive career spanning over 31 years in the pharmaceutical and related industries. He began his professional journey at Abbott in 1993, where he participated in the financial development program and gradually earned a reputation for strong financial and operational leadership.

His career continued to evolve through several critical roles at AbbVie following the company’s emergence from Abbott. He progressed through key positions including leadership in financial planning, controller functions, and executive financial roles, reflecting his deep commitment and contribution to the organization’s strategic initiatives.

In addition to his operational responsibilities, his involvement in major business developments, such as strategic acquisitions and global commercial operations, has been instrumental in shaping AbbVie's business strategy. His wide-ranging experience is further recognized through his role on the Board of Directors, allowing him to influence broader corporate governance and long-term planning.

Now, as the Chief Executive Officer since July 1, 2024, he continues to bring a wealth of experience and insight, steering the company through an evolving market landscape with a deep understanding of both financial management and operational excellence.

$ABBV Performance Under Robert A. Michael

Past Roles

Organization	Role	Date Range
AbbVie	President and Chief Operating Officer	July 2023 to June 2024
AbbVie	Vice Chairman and President	June 2022 to July 2023
AbbVie	Vice Chairman, Finance and Commercial Operations, and Chief Financial Officer	June 2021 to June 2022
AbbVie	Executive Vice President, Chief Financial Officer	2019 to 2021
AbbVie	Senior Vice President, Chief Financial Officer	2018 to 2019
AbbVie	Vice President, Controller	2017 to 2018
AbbVie	Vice President, Treasurer	2015 to 2016
AbbVie	Vice President, Controller, Commercial Operations	2013 to 2015
AbbVie	Vice President, Financial Planning and Analysis	2012 to 2013
Abbott	Division Controller, Nutrition Supply Chain	2010 to 2012

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$1,427,376	Annual	Fixed cash payment set by AbbVie’s compensation committee; does not include variable or performance-based components.

Performance Compensation

Data from FY 2023

Short-Term Incentives (PIP Bonus)

Metric	Target Details	Actual/Result Details	Weighting	Additional Details
Platform Revenue	Target: $38.8B	103% achieved; Actual: $40.0B	20%	Included in annual cash incentive evaluations.
Non-GAAP Income Before Taxes	Target: $23.1B	106% achieved; Actual: $24.4B	60%	Performance metric used for bonus payout.
Adjusted Return on Assets	Target: 19.4%	106% achieved; Actual: 20.6%	10%	Performance evaluation metric.
Non-GAAP Operating Margin	Target: $24.8B	104% achieved; Actual: $25.7B	10%	Assessed as part of incentive payout conditions.
Target Award	$2,025,000 (135% of base salary)	-	N/A	Payout capped at 170% of target; Actual Award Paid: $3,000,000.
Vesting Schedule	N/A	Annual cash incentive; no vesting schedule	N/A	Cash bonus; no deferred vesting.
Evaluation Period	Annual	N/A	N/A	Performance measured on an annual basis.

Long-Term Incentives (LTI)

Component	Metric / Details	Threshold / Target / Maximum	Grant Details & Vesting Details
Performance Shares (40% of LTI)	EPS with Relative TSR modifier	Threshold: $10.53, Target: $10.58, Maximum: $10.78; Result: $11.11 (150% payout)	3-year performance period; vesting is performance-based.
Performance-Vested RSUs (40% of LTI)	Relative ROIC	Threshold: 40th-50th percentile, Target: 50th-65th percentile, Maximum: >85th percentile; Result: 93rd percentile (200% payout)	3-year performance period; vesting is performance-based.
Non-Qualified Stock Options (20% of LTI)	Stock Price Appreciation	N/A	Vest in one-third increments on each of the first three annual anniversaries; 10-year term.
Grant Date Fair Value & Price	Fair Values: Performance Shares: $2,740,494, RSUs: $2,699,803, Options: $1,365,031	N/A	Grant Date: February 16, 2023 ; Option exercise price: $149.62, Grant Day Market Price: $149.53.